Abstract
Sleeping Beauty (SB) transposons have been effective in delivering therapeutic genes to treat certain diseases in mice. Hydrodynamic gene delivery of integrating transposons to 5-20% of the hepatocytes in a mouse results in persistent elevated expression of the therapeutic polypeptides that can be secreted into the blood for activity throughout the animal. An alternative route of delivery is ex vivo transformation with SB transposons of hematopoietic cells, which then can be reintroduced into the animal for treatment of cancer. We discuss issues associated with the scale-up of hydrodynamic delivery to the liver of larger animals as well as ex vivo delivery. Based on our and others experience with inefficient delivery to larger animals, we hypothesize that impulse, rather than pressure, is a critical determinant of the effectiveness of hydrodynamic delivery. Accordingly, we propose some alterations in delivery strategies that may yield efficacious levels of gene delivery in dogs and swine that will be applicable to humans. To ready hydrodynamic delivery for human application we address a second issue facing transposons used for gene delivery regarding their potential to “re-hop” from one site to another and thereby destabilize the genome. The ability to correct genetic diseases through the infusion of DNA plasmids remains an appealing goal.
Keywords: Sleeping Beauty transposons, hydrodynamic gene delivery, non-viral gene delivery, chimeric antigen receptors, T-cells, clinical applications, episomal DN, SB transposon, chromosome, SB100X
Current Gene Therapy
Title: Efficacy and Safety of Sleeping Beauty Transposon-Mediated Gene Transfer in Preclinical Animal Studies
Volume: 11 Issue: 5
Author(s): Perry B. Hackett, Elena L. Aronovich, David Hunter, Myra Urness, Jason B. Bell, Steven J. Kass, Laurence J.N. Cooper and Scott McIvor
Affiliation:
Keywords: Sleeping Beauty transposons, hydrodynamic gene delivery, non-viral gene delivery, chimeric antigen receptors, T-cells, clinical applications, episomal DN, SB transposon, chromosome, SB100X
Abstract: Sleeping Beauty (SB) transposons have been effective in delivering therapeutic genes to treat certain diseases in mice. Hydrodynamic gene delivery of integrating transposons to 5-20% of the hepatocytes in a mouse results in persistent elevated expression of the therapeutic polypeptides that can be secreted into the blood for activity throughout the animal. An alternative route of delivery is ex vivo transformation with SB transposons of hematopoietic cells, which then can be reintroduced into the animal for treatment of cancer. We discuss issues associated with the scale-up of hydrodynamic delivery to the liver of larger animals as well as ex vivo delivery. Based on our and others experience with inefficient delivery to larger animals, we hypothesize that impulse, rather than pressure, is a critical determinant of the effectiveness of hydrodynamic delivery. Accordingly, we propose some alterations in delivery strategies that may yield efficacious levels of gene delivery in dogs and swine that will be applicable to humans. To ready hydrodynamic delivery for human application we address a second issue facing transposons used for gene delivery regarding their potential to “re-hop” from one site to another and thereby destabilize the genome. The ability to correct genetic diseases through the infusion of DNA plasmids remains an appealing goal.
Export Options
About this article
Cite this article as:
B. Hackett Perry, L. Aronovich Elena, Hunter David, Urness Myra, B. Bell Jason, J. Kass Steven, J.N. Cooper Laurence and McIvor Scott, Efficacy and Safety of Sleeping Beauty Transposon-Mediated Gene Transfer in Preclinical Animal Studies, Current Gene Therapy 2011; 11 (5) . https://dx.doi.org/10.2174/156652311797415827
DOI https://dx.doi.org/10.2174/156652311797415827 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Neuroprotection in Cardiac Surgery: Effectiveness of Pharmacologic-Preconditioning with Erythromycin
Current Vascular Pharmacology Muscle Metabolism and Exercise Capacity in Cachexia
Current Pharmaceutical Design miR-25 Mediates Retinal Degeneration Via Inhibiting ITGAV and PEDF in Rat
Current Molecular Medicine Synthesis and Altered Biodistribution of 99mTc Labeled Vincristine in Animal Model
Current Medical Imaging Advancements in Treatment Options of Women Infertility
Current Women`s Health Reviews Dronedarone: A Safety Comparison to Amiodarone
Current Drug Safety Remyelination in Multiple Sclerosis: The Therapeutic Potential of Neural and Mesenchymal Stem/Progenitor Cells
Current Signal Transduction Therapy Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Statins and Left Ventricular Function
Current Pharmaceutical Design Diabetes and Vascular Disease: Is It All About Glycemia?
Current Pharmaceutical Design Enhanced Proinflammatory State and Autoimmune Activation: a Breakthrough to Understanding Chronic Diseases
Current Pharmaceutical Design Cardiovascular Aspect of Beta-Thalassaemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Adverse Effects of Cigarette Smoke and Induction of Oxidative Stress in Cardiomyocytes and Vascular Endothelium
Current Pharmaceutical Design Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors
Current Medicinal Chemistry Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Analogy of Cardiac and Renal Complications in Essential Hypertension and Aged SHR or L-NAME/SHR
Medicinal Chemistry Nutrient and Qualitative Phytochemical Analysis-evaluation of Antimicrobial Activity and Development of Products with Mulberry Leaves (<i>Mulberry indica</i> L.)
Current Nutrition & Food Science Recent Valves used for Transluminal Implantation in Patients with Aortic Valve Stenosis
Recent Patents on Cardiovascular Drug Discovery Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry What Makes Y Family Pols Potential Candidates for Molecular Targeted Therapies and Novel Biotechnological Applications
Current Molecular Medicine